Oncology
NEC Bio Therapeutics GmbH focuses its clinical research on solid tumors, with studies centered on advanced disease settings and tumor types that require new treatment options.
- Advanced solid tumors
- Triple negative breast cancer
The sponsor’s research activity in this area includes multicenter clinical programs across multiple countries and collaborating sites.
Breast Cancer
Within oncology, the sponsor has a specific interest in triple negative breast cancer, a biologically aggressive subtype with limited targeted treatment options.
- Neoadjuvant treatment
- Immune-based combinations
Its clinical work in this field is directed toward treatment strategies used alongside established anti-PD-1 therapy.
Immuno-oncology
The sponsor is actively involved in immune checkpoint inhibitor combinations, with research that integrates PD-1 and PD-L1 directed therapies in cancer care.
- PD-1 inhibitor therapy
- PD-L1 inhibitor therapy
This area reflects a therapeutic focus on enhancing anti-tumor immune responses in both breast cancer and broader solid tumor populations.
Therapeutic Cancer Vaccines
NEC Bio Therapeutics GmbH also supports research into cancer vaccine approaches, particularly add-on strategies intended for use with immunotherapy in oncology.
- NECVAX-NEO1
- Combination immunotherapy
These studies place emphasis on novel immune-directed interventions for patients with advanced malignancies.
